Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Canara's Q2 profit rides 20% NII jump to ₹11,005 cr

Canara Bank announced a Q2 net profit of Rs 5,175 crore, a 8% increase from Rs 4,774 crore in the same period last year, on Wednesday. This profit surge was driven by a 20% jump in net interest income (NII) to Rs 11,005 crore, up from Rs 9,141 crore YoY. The company's shares gained nearly 5% on the news, reaching Rs 126.44. However, operating profit margin declined to 21.40% from 22.25%, while net profit margin slightly increased to 12.64% from 12.37%.

Canara Bank's asset quality improved, with net non-performing assets (NNPA) dropping 34% YoY to Rs 4,053 crore and gross performing assets (GNPA) falling 32% YoY to Rs 18,299 crore. Consequently, the gross NPA ratio decreased to 1.33% from 2.35%. Annualised return on assets (RoA) stood at 1.05% in Q2 FY27, a slight dip from 1.10% in the previous period.

The bank's debt-equity ratio improved to 0.52%, down from 0.55%. Provisions decreased by 6% YoY to Rs 3,583 crore, while quarterly net interest margin (NIM) was 2.55% compared to 2.5% in the prior year. The cost of funds (CoF) dropped to 4.88% from 5.21%. Canara Bank's cost of deposits ratio also fell to 5.27%. Its slippage ratio eased to 0.15% from 0.19%.

While overall business performance is expected to meet the FY27 guidance, the CASA ratio was 29%, slightly below the 30-32% target.

Written by urgent.news from The Economic Times's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at economictimes.indiatimes.com →

More in Finance & Markets

[Yuhan] Proof needed for Lazertinib numbers and subsequent growth narrative

The author is an analyst for NH Investment & Securities. He can be reached at seungyeon.han@nhsec.com -- Ed.Three pre-conditions for sustained rebound: Defensiveness, royalties, and global L/O dealsWe…

  • Yuhan maintains Buy rating and W110,000 target price from NH Investment & Securities
  • PALOMA-2 trial showed ORR of 90%, mPFS of 26.1 months, and 3-year OS rate of 70%

More from Wednesday 14 October →